Zanamed Medical Clinic Sp. z o.o.
- Address
- lock Available on a paid plan
Zanamed Medical Clinic - Multi-Specialty Clinical Research Center
Zanamed Medical Clinic Sp. z o.o. is a distinguished clinical research facility specializing in diverse therapeutic areas with particular expertise in cardiovascular, respiratory, and metabolic disorders. The center conducts sophisticated Phase 2 and Phase 3 clinical trials, demonstrating capabilities in complex disease management including chronic kidney disease, heart failure, and multiple endocrine conditions. Their research portfolio reflects a commitment to evaluating novel therapeutic approaches and innovative drug delivery systems across multiple disease states.
- Cardiovascular research focusing on heart failure therapies and combination treatment strategies with novel compounds
- Respiratory medicine including COPD clinical trials evaluating triple therapy combinations and advanced inhaler technologies
- Metabolic and endocrine disorders with emphasis on diabetes management, including Type 1 diabetes and chronic kidney disease
- Dermatology and immunology trials for moderate to severe plaque psoriasis and relapsing multiple sclerosis
The clinic demonstrates particular strength in conducting long-term safety and efficacy studies, including extension trials that assess durability of response and safety profiles over extended treatment periods. Their research experience encompasses rare pulmonary conditions such as idiopathic pulmonary fibrosis, oncology trials for esophageal squamous cell carcinoma, and advanced immunomodulatory therapies. This broad therapeutic expertise, combined with capabilities in complex dosing regimens and multi-arm comparative studies, positions Zanamed as a versatile clinical research partner capable of managing sophisticated trial designs across multiple medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zanamed Medical Clinic Sp. z o.o.
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.